U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H15NO3S
Molecular Weight 217.285
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAPTOPRIL

SMILES

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

InChIKey=FAKRSMQSSFJEIM-RQJHMYQMSA-N
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

HIDE SMILES / InChI

Molecular Formula C9H15NO3S
Molecular Weight 217.285
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C66443

Pivalopril (RHC 3659-(S); (S)-N-cyclopentyl-N-(2-methyl-3-pivaloylthiopropionyl) glycine) is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, the free SH metabolite of pivopril competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Pivopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Pivalopril has been compared to captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produced a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for pivalopriland captopril was 0.1 mg/kg. Pivalopril has being shown to be a potent, orally effective ACE inhibitor and antihypertensive agent.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CAPOTEN

Approved Use

Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide­ type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).

Launch Date

1981
Primary
CAPOTEN

Approved Use

Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide­ type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).

Launch Date

1981
Primary
CAPOTEN

Approved Use

Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide­ type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).

Launch Date

1981
Primary
CAPOTEN

Approved Use

Hypertension: CAPOTEN (captopril tablets, USP) is indicated for the treatment of hypertension. In using CAPOTEN, consideration should be given to the risk of neutropenia/agranulocytosis. CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide­ type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: CAPOTEN is indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: CAPOTEN is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: CAPOTEN is indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. CAPOTEN decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).

Launch Date

1981
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
878 μg/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
824 μg/L
100 mg 3 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.31 μg/mL
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
800 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
230 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL DISULFIDE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
385 ng/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
499 ng/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1235 μg × h/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1197 μg × h/L
100 mg 3 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
20.1 μg × h/L/(mg dose)
2.5 mg single, intravenous
dose: 2.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
21 μg × h/L/(mg dose)
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
20.5 μg × h/L/(mg dose)
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1150 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
260 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL DISULFIDE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
870 ng × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1067 ng × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.2 h
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.1 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CAPTOPRIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.66 h
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.9 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAPTOPRIL plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: FASTED
0.83 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.83 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: HYDROCHLOROTHIAZIDE
CAPTOPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
33%
CAPTOPRIL serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
50 mg 1 times / day multiple, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 54 years (range: 39-65 years)
Health Status: unhealthy
Age Group: 54 years (range: 39-65 years)
Sources:
50 mg 1 times / day multiple, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 65 years
Health Status: unhealthy
Age Group: 65 years
Sex: F
Sources:
Disc. AE: Eruption lichenoid...
AEs leading to
discontinuation/dose reduction:
Eruption lichenoid (severe, 1 patient)
Sources:
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Sources:
healthy, 22
Health Status: healthy
Age Group: 22
Sex: M
Sources:
Disc. AE: Hypotension, Loss of consciousness...
AEs leading to
discontinuation/dose reduction:
Hypotension
Loss of consciousness
Sources:
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: F
Sources:
Disc. AE: Hypotension, Drowsiness...
AEs leading to
discontinuation/dose reduction:
Hypotension
Drowsiness
Sources:
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Disc. AE: Cough, Failure heart...
AEs leading to
discontinuation/dose reduction:
Cough (3.8%)
Failure heart (2.4%)
Hyperkalaemia (1.6%)
Taste perversion
Decreased appetite
Rash (1%)
Hypotension (1.4%)
Angio-oedema (0.8%)
Arrhythmia (1%)
Myocardial infarction (1%)
Kidney dysfunction (0.8%)
Stroke (0.8%)
Angina (0.5%)
Sources:
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M
Sources:
Disc. AE: Urticaria, Hypotension...
AEs leading to
discontinuation/dose reduction:
Urticaria (1.2%)
Hypotension (2.5%)
Sources:
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Disorder fetal...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Sources:
AEs

AEs

AESignificanceDosePopulation
Eruption lichenoid severe, 1 patient
Disc. AE
50 mg 1 times / day multiple, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 65 years
Health Status: unhealthy
Age Group: 65 years
Sex: F
Sources:
Hypotension Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Sources:
healthy, 22
Health Status: healthy
Age Group: 22
Sex: M
Sources:
Loss of consciousness Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Sources:
healthy, 22
Health Status: healthy
Age Group: 22
Sex: M
Sources:
Drowsiness Disc. AE
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: F
Sources:
Hypotension Disc. AE
500 mg single, oral
Overdose
Dose: 500 mg
Route: oral
Route: single
Dose: 500 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: F
Sources:
Angina 0.5%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Angio-oedema 0.8%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Kidney dysfunction 0.8%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Stroke 0.8%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Arrhythmia 1%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Myocardial infarction 1%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Rash 1%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Hypotension 1.4%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Hyperkalaemia 1.6%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Failure heart 2.4%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Cough 3.8%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Decreased appetite Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Taste perversion Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 73
Health Status: unhealthy
Age Group: 73
Sex: M+F
Sources:
Urticaria 1.2%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M
Sources:
Hypotension 2.5%
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M
Sources:
Disorder fetal Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives.
1985 Jan
Spatial and temporal analysis of left ventricular filling flow propagation in hypertensive patients before and after regression of myocardial hypertrophy with alacepril therapy.
2001 Aug
Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure.
2002 Dec
Effects of acute and chronic alacepril treatment on exercise capacity and hemodynamics in patients with heart failure: a preliminary study.
2002 Feb
Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril.
2003 Aug
The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha.
2004
Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure.
2008 Jan
[Successful extubation in a patient with alacepril-induced tongue angioedema].
2010 Apr
Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
2016 Sep
Pharmacodynamics of alacepril in healthy cats.
2017 Jun
Effects of the angiotensin-converting enzyme inhibitor alacepril in dogs with mitral valve disease.
2018 Aug 10
Effects of high-dose alacepril on left atrial pressure and central aortic pressure in awake dogs with mitral valve regurgitation.
2019 Mar
Patents

Sample Use Guides

Single oral dose (5 - 80 mg)
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:56:19 GMT 2025
Edited
by admin
on Mon Mar 31 17:56:19 GMT 2025
Record UNII
9G64RSX1XD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAPTOPRIL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
APOPRIL
Preferred Name English
CAPOTEN
Brand Name English
CAPTOPRIL [WHO-IP]
Common Name English
CAPTOPRIL [MART.]
Common Name English
CAPTOPRIL [USP MONOGRAPH]
Common Name English
Captopril [WHO-DD]
Common Name English
SA-333
Code English
GARRANIL
Common Name English
1-((2S)-3-MERCAPTO-2-METHYLPROPIONYL)-L-PROLINE
Systematic Name English
SQ-14225
Code English
TENSIOMIN
Common Name English
CAPTOMAX
Common Name English
CAPTOPRIL [USP-RS]
Common Name English
SQ -14225
Code English
CAPTOPRIL [USAN]
Common Name English
CAPTOPRIL [HSDB]
Common Name English
CAPTOPRILUM [WHO-IP LATIN]
Common Name English
C09AA01
Code English
FARCOPRIL
Common Name English
CAPTOPRIL [EP MONOGRAPH]
Common Name English
CAPTOPRIL [MI]
Common Name English
L-PROLINE, 1-((2S)-3-MERCAPTO-2-METHYL-1-OXOPROPYL)-
Systematic Name English
ZAPTO
Common Name English
MEPHA
Common Name English
CAPTOPRIL [USP IMPURITY]
Common Name English
CAPTOPRIL [VANDF]
Common Name English
CAPTOPRIL [ORANGE BOOK]
Common Name English
NSC-757419
Code English
CAPTOPRIL [JAN]
Common Name English
HYPOPRESS
Common Name English
captopril [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC C09AA01
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
WHO-ATC C09BA01
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
NDF-RT N0000000181
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
NDF-RT N0000175562
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
WHO-VATC QC09AA01
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
WHO-VATC QC09BA01
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
NCI_THESAURUS C247
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
LIVERTOX NBK548504
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
Code System Code Type Description
MESH
D002216
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
CHEBI
3380
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
NCI_THESAURUS
C340
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
RXCUI
1998
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
263-607-1
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
MERCK INDEX
m3046
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY Merck Index
INN
4373
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
ChEMBL
CHEMBL1560
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
WIKIPEDIA
CAPTOPRIL
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
DAILYMED
9G64RSX1XD
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
SMS_ID
100000092557
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
IUPHAR
5158
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
DRUG CENTRAL
484
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CAPTOPRIL
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder. Solubility: Freely soluble in water, dichloromethane R, and methanol R. Category: Cardiovascular agent; angiotensin-converting enzyme inhibitor. Storage: Captopril should be kept in a tightly closed container, protected from light. Additional information: Captopril may exist in different polymorphic forms. Requirement: Captopril contains not less than 98.0% and not more than 102.0% of C9H15NO3S, calculated with reference to the dried substance.
NSC
757419
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
EVMPD
SUB06081MIG
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
HSDB
6527
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
FDA UNII
9G64RSX1XD
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
DRUG BANK
DB01197
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
RS_ITEM_NUM
1091200
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
CAS
62571-86-2
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID1037197
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
PUBCHEM
44093
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
LACTMED
Captopril
Created by admin on Mon Mar 31 17:56:19 GMT 2025 , Edited by admin on Mon Mar 31 17:56:19 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
Binding Assay
IC50
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC